- NSE
Biocon Limited
Healthcare BIOCON
366.80INR
1.50
(
0.41%)
Last update at 2026-01-30 15:59:11
Day Range
52 Week Range
Fundamentals
- Previous Close 365.30
- Market Cap 569444.73M
- Volume1,851,119
- P/E Ratio 94.72
- EBITDA 33891.00M
- Revenue TTM 164758.00M
- Revenue Per Share TTM 132.54
- Gross Profit TTM 98714.00M
- Diluted EPS TTM 3.99
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Past Performance
| Status | Stocks | Entry Price | Entry Date | Exit Date | Duration | Duration Type | Sector | *Return(%) |
|---|---|---|---|---|---|---|---|---|
| CLOSED | BIOCON | ₹ 315.70 | 11/04/25 | 11/04/25 | Same Day | Short Term | Healthcare | 0.46% |
| CLOSED | BIOCON | ₹ 314.45 | 8/04/25 | 8/04/25 | Same Day | Short Term | Healthcare | 1.24% |
| CLOSED | BIOCON | ₹ 340.30 | 17/02/25 | 3/04/25 | 45 Days | Short Term | Healthcare | 5.02% |
| CLOSED | BIOCON | ₹ 365.20 | 13/01/25 | 13/01/25 | Same Day | Short Term | Healthcare | 3.37% |
Financials
Income Statement
Balance Sheet
Change in Cash
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Income before tax | 18866.00M | 15252.00M | 8971.00M | 9831.00M | 10774.00M |
| Net income | 10133.00M | 10225.00M | 4627.00M | 6484.00M | 7405.00M |
| Total Revenue | 152617.00M | 147557.00M | 111742.00M | 80248.00M | 69701.00M |
| Gross Profit | 92441.00M | 91735.00M | 75111.00M | 53012.00M | 47599.00M |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Total assets | 587973.00M | 560707.00M | 520428.00M | 203940.00M | 185223.00M |
| Intangible assets | 102719.00M | 102867.00M | 105259.00M | 12887.00M | 11736.00M |
| Other current assets | 8466.00M | 13918.00M | 5880.00M | 4207.00M | 3638.00M |
| Deferred long term liab | - | - | - | - | - |
| Non current assets other | - | - | - | - | - |
| Breakdown | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 | 2021-03-31 |
| Change in Cash | 20043.00M | -3804.00M | 6411.00M | -2433.00M | 723.00M |
| Operating Cash | 40612.00M | 29539.00M | 18525.00M | 11766.00M | 11597.00M |
| Free Cash Flow | 17179.00M | 10223.00M | 1262.00M | -7482.00M | -5866.00M |
Peer Comparison
Sector: Healthcare Industry: Biotechnology
| Company | Change | Price | Market Cap (M) | P/E Ratio |
|---|---|---|---|---|
| BIOCON Biocon Limited |
1.50 0.41% | 366.80 | 569444.73 | 94.72 |
| ANTHEM Anthem Biosciences Ltd |
-0.65 -0.11% | 606.75 | 416096.85 | 91.92 |
| ONESOURCE ONESOURCE SPECIALTY PHARMA LTD |
41.20 3.50% | 1218.80 | 203986.14 | 501.41 |
| CONCORDBIO Concord Biotech Limited |
19.10 1.64% | 1183.20 | 140309.66 | 43.31 |
| BLUEJET Blue Jet Healthcare Limited |
-8.30 -1.97% | 413.00 | 89232.91 | 25.36 |
Profile
Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, adalimumab, etanercept, ustekinumab, glargine, aspart, insulins, and aflibercept. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer goods, and agrochemical companies. In addition, the company offers enzyme, biopharmaceutical, and medicinal goods; contract research and manufacturing services, and other research and development in the fields of pharmaceuticals, drug discovery, biotechnology pharmaceuticals, and medicinal sciences, etc.; clinical research; and business support and development, and marketing services. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.
Biocon Limited
20th KM, Hosur Road, Bengaluru, India, 560100
- 91 80 2808 2808
- https://www.biocon.com
- Employees : N/A
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Kiran Mazumdar-Shaw B.Sc (Hons), B.Sc. | Founder & Exec. Chairperson | 1953 |
| Mr. Siddharth Mittal BCom, CA, CPA | MD, CEO & Director | 1978 |
| Mr. Indranil Sen | Chief Financial Officer | NA |
| S. Vijaya Kumar | Head of Operations | NA |
| Mr. Saurabh Paliwal | Head of Investor Relations | NA |
| Mr. Mayank Verma | Company Sec. & Compliance Officer | NA |
| Ms. Seema Shah Ahuja BA, MBA | Global Head of Communications & Corp. Brand | 1966 |
| Mr. Amitava Saha | Chief HR Officer | 1970 |
| Mr. Sandeep Rao M.Sc., PGDM | Sr. VP | 1973 |
| Dr. A. V. Sriram | Head of Quality | 1963 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data ("EODHD") on an 'as is' basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.